- Scott Gottlieb
- New York
The diuretic spironolactone can cause dangerous hyperkalaemia in patients who are also taking angiotensin converting enzyme (ACE) inhibitors, another drug that, like spironolactone, is used to treat congestive heart failure.
After the publication of a major heart study that promoted the use of spironolactone, prescribing rose, but so did cases of hyperkalaemia, according to Dr David Juurlink, a clinical pharmacologist at the University of Toronto and author of a new study that found a threefold increase in the rates of admission to hospital for high potassium levels across Ontario and a twofold increase in deaths involving high potassium levels (New England Journal of Medicine 2004;351:543-51).
The randomised aldactone evaluation study (RALES), which was reported in 1999, found …
Sign in
Personal subscribers, sign in here:
Article access
Article access for 1 day
Purchase this article for £20 $30 €32*
The PDF version can be downloaded as your personal record
CiteULike
Connotea
Del.icio.us
Digg
Facebook
Reddit
Technorati
Twitter
Stumbleupon
Rapid responses
Latest Responses
Re: Sir Karl Popper, swans, and the general practitioner
Published 6 February 2012
The TBAS cost effectiveness is not proven beyond the experimental contest
Published 6 February 2012
Re: Why legislation is necessary for my health reforms
Published 6 February 2012
Re: Dual renin-angiotensin system blockade
Published 6 February 2012
Re: Why legislation is necessary for my health reforms
Published 6 February 2012
Most responses
Does anyone understand the government’s plan for the NHS? (17 responses)
Published 17 Jan 2012
Bad medicine: medical nutrition (15 responses)
Published 18 Jan 2012
Wakefield sues BMJ over MMR articles (5 responses)
Published 10 Jan 2012
Why legislation is necessary for my health reforms (5 responses)
Published 1 Feb 2012
Scientific misconduct is worryingly prevalent in the UK, shows BMJ survey (4 responses)
Published 12 Jan 2012